Mesoblast Limited Overview
Pro stress-test →Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The biopharmaceutical company engages in research, development, and market of mesenchymal lineage adult stem cell technology platform, with medicines targeting cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases.
Strategic Profile
Pro stress-test →The company is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms, with Ryoncil being developed for SR-aGvHD in adults and biologic-resistant inflammatory bowel disease, and rexlemestrocel-L for heart failure and chronic low back pain. Strategic partnerships include agreements with Tasly Pharmaceutical Group, JCR Pharmaceuticals Co. Ltd., and Grünenthal for development and commercialization across multiple therapeutic areas.
Competitive Landscape
Pro stress-test →Mesoblast operates in the emerging allogeneic cell therapy space with limited direct competitors offering similar off-the-shelf cellular medicine platforms. Key competitive dynamics involve differentiation through IP strength, manufacturing capabilities, and clinical efficacy in inflammatory indications. The company competes indirectly with biologics, small molecule pharmaceuticals, and other cell therapy developers targeting similar disease areas.
Industry Context
Mesoblast Limited operates in Biopharmaceutical - Cell Therapy / Regenerative Medicine.
Key facts
Founded: 2004 · Headquarters: Melbourne, Australia · Employees: 81 · Revenue: AUD 21.32M (last half-year)